

**REMARKS**

Claims 48-66 have been canceled without prejudice or disclaimer. Therefore, claims 77-96 are pending in the present application. Claim 77 has been amended as suggested by the Examiner.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

**I. The Rejections of Claims 48-53, 56-62, 65, 66, 77-82, 85 and 86 under 35 U.S.C. 102 and/or 103**

The Office maintained the rejection of claims 48-50, 56-59, 65, 66, 77-79, 85-89, 95 and 96 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Ladner et al. (U.S. Patent No. 5,223,409). The Office also maintained the rejection of claims 51-53, 60-62, 80-82 and 90-92 under 35 U.S.C. 103(a) as being obvious over Ladner et al. in view of either Zachariae et al. (Allergy, Vol. 36, pp. 513-516 (1981)) or Arlian et al. (Int. Arch. Allergy Appl. Immunol., Vol. 91, pp. 278-284 (1990)). These rejections are respectfully traversed for the reasons of record.


However, in order to advance prosecution, claims 48-66 have been cancelled without prejudice or disclaimer. Furthermore, claim 77 has been amended as suggested by the Examiner. Applicants therefore submit that all claims are in condition for allowance.

**II. Conclusion**

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 20, 2003



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097